SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Kraig Biocraft Laboratories, Inc – ‘S-1’ on 6/2/20 – ‘EX-99.2’

On:  Tuesday, 6/2/20, at 4:47pm ET   ·   Accession #:  1493152-20-10402   ·   File #:  333-238883

Previous ‘S-1’:  ‘S-1/A’ on 6/2/15   ·   Next:  ‘S-1/A’ on 8/24/20   ·   Latest:  ‘S-1/A’ on 11/22/23   ·   22 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 6/02/20  Kraig Biocraft Laboratories, Inc  S-1                   71:7.9M                                   M2 Compliance/FA

Registration Statement (General Form)   —   Form S-1
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: S-1         Registration Statement (General Form)               HTML   1.20M 
 2: EX-14.2     Code of Ethics                                      HTML     72K 
 3: EX-23.1     Consent of Experts or Counsel                       HTML     21K 
 4: EX-99.1     Miscellaneous Exhibit                               HTML     61K 
 5: EX-99.2     Miscellaneous Exhibit                               HTML     47K 
 6: EX-99.3     Miscellaneous Exhibit                               HTML     42K 
14: R1          Document Entity Information                         HTML     34K 
48: R2          Condensed Consolidated Balance Sheets               HTML    120K 
58: R3          Condensed Consolidated Balance Sheets               HTML     49K 
                (Parenthetical)                                                  
31: R4          Condensed Consolidated Statements of Operations     HTML     89K 
15: R5          Condensed Consolidated Statement of Changes in      HTML     79K 
                Stockholders Deficit                                             
49: R6          Condensed Consolidated Statement of Changes in      HTML     25K 
                Stockholders Deficit (Parenthetical)                             
59: R7          Condensed Consolidated Statements of Cash Flows     HTML    110K 
32: R8          Summary of Significant Accounting Policies and      HTML    114K 
                Organization                                                     
13: R9          Going Concern                                       HTML     28K 
37: R10         Equipment                                           HTML     35K 
20: R11         Right to Use Assets and Lease Liability             HTML     56K 
50: R12         Accrued Interest - Related Party                    HTML     32K 
60: R13         Note Payable                                        HTML     28K 
38: R14         Stockholders' Deficit                               HTML    157K 
21: R15         Commitments and Contingencies                       HTML     81K 
51: R16         Related Party Transactions                          HTML     63K 
61: R17         Subsequent Events                                   HTML     29K 
39: R18         Summary of Significant Accounting Policies and      HTML    153K 
                Organization (Policies)                                          
19: R19         Summary of Significant Accounting Policies and      HTML     62K 
                Organization (Tables)                                            
41: R20         Equipment (Tables)                                  HTML     33K 
66: R21         Right to Use Assets and Lease Liability (Tables)    HTML     40K 
26: R22         Stockholders' Deficit (Tables)                      HTML    145K 
22: R23         Summary of Significant Accounting Policies and      HTML     49K 
                Organization (Details Narrative)                                 
42: R24         Summary of Significant Accounting Policies and      HTML     43K 
                Organization (Details Narrative) (10-K)                          
67: R25         Summary of Significant Accounting Policies and      HTML     30K 
                Organization - Schedule of Antidilutive Securities               
                of Earnings Per Share (Details)                                  
27: R26         Summary of Significant Accounting Policies and      HTML     28K 
                Organization - Schedule of Antidilutive Securities               
                of Earnings Per Share (Details) (Parenthetical)                  
23: R27         Summary of Significant Accounting Policies and      HTML     35K 
                Organization - Schedule of Deferred Tax Assets and               
                Liabilities (Details) (10-K)                                     
40: R28         Summary of Significant Accounting Policies and      HTML     24K 
                Organization - Schedule of Deferred Tax Assets and               
                Liabilities (Details) (10-K) (Parenthetical)                     
68: R29         Summary of Significant Accounting Policies and      HTML     31K 
                Organization - Schedule of Components of Deferred                
                Income Taxes (Details) (10-K)                                    
64: R30         Summary of Significant Accounting Policies and      HTML     28K 
                Organization - Schedule of Fair Value of Financial               
                Instruments (Details)                                            
54: R31         Summary of Significant Accounting Policies and      HTML     34K 
                Organization - Schedule of Concentration of Credit               
                Risk (Details) (10-K)                                            
18: R32         Going Concern (Details Narrative)                   HTML     33K 
36: R33         Going Concern (Details Narrative) (10-K)            HTML     33K 
63: R34         Equipment (Details Narrative)                       HTML     25K 
53: R35         Equipment (Details Narrative) (10-K)                HTML     25K 
17: R36         Equipment - Schedule of Property and Equipment      HTML     37K 
                (Details)                                                        
35: R37         Right to Use Assets and Lease Liability - (Details  HTML     59K 
                Narrative)                                                       
62: R38         Right to Use Assets and Lease Liability - (Details  HTML     65K 
                Narrative) (10-K)                                                
55: R39         Right to Use Assets and Lease Liability - Schedule  HTML     28K 
                of Right Use of Assets (Details)                                 
71: R40         Right to Use Assets and Lease Liability - Schedule  HTML     33K 
                of Lease Liability (Details)                                     
44: R41         Right to Use Assets and Lease Liability - Schedule  HTML     27K 
                of Lease Cost (Details)                                          
25: R42         Accrued Interest - Related Party (Details           HTML     45K 
                Narrative)                                                       
30: R43         Accrued Interest - Related Party (Details           HTML     45K 
                Narrative) (10-K)                                                
70: R44         Note Payable (Details Narrative)                    HTML     41K 
43: R45         Note Payable (Details Narrative) (10-K)             HTML     41K 
24: R46         Stockholders' Deficit (Details Narrative)           HTML    186K 
29: R47         Stockholders' Deficit (Details Narrative) (10-K)    HTML    179K 
69: R48         Stockholders' Deficit - Schedule of Option          HTML     86K 
                Assumption (Details)                                             
45: R49         Stockholders' Deficit - Schedule of Warrants        HTML     52K 
                Activity (Details)                                               
46: R50         Stockholders' Deficit - Schedule of Warrants        HTML     59K 
                Outstanding (Details)                                            
56: R51         Stockholders' Deficit - Schedule of Options         HTML     31K 
                Outstanding (Details)                                            
33: R52         Commitments and Contingencies (Details Narrative)   HTML    355K 
16: R53         Commitments and Contingencies (Details Narrative)   HTML    311K 
                (10-K)                                                           
47: R54         Related Party Transactions (Details Narrative)      HTML    272K 
57: R55         Related Party Transactions (Details Narrative)      HTML    293K 
                (10-K)                                                           
34: R56         Subsequent Events (Details Narrative) (10-K)        HTML     35K 
65: XML         IDEA XML File -- Filing Summary                      XML    128K 
28: EXCEL       IDEA Workbook of Financial Reports                  XLSX     95K 
 7: EX-101.INS  XBRL Instance -- kblb-20200331                       XML   2.05M 
 9: EX-101.CAL  XBRL Calculations -- kblb-20200331_cal               XML    133K 
10: EX-101.DEF  XBRL Definitions -- kblb-20200331_def                XML    814K 
11: EX-101.LAB  XBRL Labels -- kblb-20200331_lab                     XML    909K 
12: EX-101.PRE  XBRL Presentations -- kblb-20200331_pre              XML    959K 
 8: EX-101.SCH  XBRL Schema -- kblb-20200331                         XSD    178K 
52: ZIP         XBRL Zipped Folder -- 0001493152-20-010402-xbrl      Zip    146K 


‘EX-99.2’   —   Miscellaneous Exhibit


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



 

Exhibit 99.2

 

CHARTER OF THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS OF

KRAIG BIOCRAFT LABORATORIES, INC.

 

(Adopted by the Board of Directors of Kraig Biocraft Laboratories, Inc. (the “Company”) on [ ], 2020; effective upon the effectiveness of the Company’s registration statement on Form S-1 relating to the uplisting of its common stock and certain warrants on the Nasdaq Capital Market)

 

 

 

I. PURPOSE OF THE COMMITTEE

 

The purposes of the Company’s Compensation Committee (the “Committee”) of the Board of Directors (the “Board”) shall be to oversee the Company’s compensation and employee benefit plans and practices, including its executive compensation plans, and to perform such further functions as may be consistent with this Charter or assigned by applicable law, the Company’s articles of incorporation or bylaws or the Board.

 

II. COMPOSITION OF THE COMMITTEE

 

The Committee shall consist of three (3) or more directors as determined from time to time by the Board. Each member of the Committee shall be qualified to serve on the Committee pursuant to the requirements of the Nasdaq, and any additional requirements that the Board deems appropriate. Composition of the Committee shall also comply with any other applicable laws and regulations. In addition, in affirmatively determining the independence of any director who will serve on the Committee, the Board must consider all factors specifically relevant to determining whether a director has a relationship to the Company which is material to that director’s ability to be independent from management in connection with the duties of a Committee member, including but not limited to (i) the source of compensation of such director, including any consulting, advisory or other compensatory fee paid by the Company to such director; and (ii) whether such director is affiliated with the Company, a subsidiary of the Company or an affiliated of a subsidiary of the Company.

 

The chairperson of the Committee shall be designated by the Board. Any vacancy on the Committee shall be filled by majority vote of the Board. No member of the Committee shall be removed except by majority vote of the Board.

 

III. MEETINGS AND PROCEDURES OF THE COMMITTEE

 

The Committee shall meet as often as it determines necessary to carry out its duties and responsibilities, but no less than once annually. The Committee, in its discretion, may ask members of management or others to attend its meetings (or portions thereof) and to provide pertinent information as necessary, provided, that the Chief Executive Officer of the Company may not be present during any portion of a Committee meeting in which deliberation or any vote regarding his or her compensation occurs.

 

 C: 
  C: 1 
   

 

A majority of the members of the Committee present in person or by means of a conference telephone or other communications equipment by means of which all persons participating in the meeting can hear each other shall constitute a quorum.

 

The Committee shall maintain minutes of its meetings and records relating to those meetings and shall report regularly to the Board on its activities, as appropriate.

 

IV. DUTIES AND RESPONSIBILITIES OF THE COMMITTEE

 

A. Executive Compensation

 

The Committee shall have the following duties and responsibilities with respect to the Company’s executive compensation plans:

 

  a) To review at least annually the goals and objectives of the Company’s executive compensation plans, and amend, or recommend that the Board amend, these goals and objectives if the Committee deems it appropriate.
     
  b) To review at least annually the Company’s executive compensation plans in light of the Company’s goals and objectives with respect to such plans, and, if the Committee deems it appropriate, adopt, or recommend to the Board the adoption of, new, or the amendment of existing, executive compensation plans.
     
  c) To evaluate annually the performance of the Chief Executive Officer in light of the goals and objectives of the Company’s executive compensation plans, and, either as a Committee or together with the other independent directors (as directed by the Board), determine and approve the Chief Executive Officer’s compensation level based on this evaluation. In determining the long-term incentive component of the Chief Executive Officer’s compensation, the Committee shall consider factors as it determines relevant, which may include, for example the Company’s performance and relative shareholder return, the value of similar awards to chief executive officers of comparable companies, and the awards given to the Chief Executive Officer of the Company in past years. The Committee may discuss the Chief Executive Officer’s compensation with the Board if it chooses to do so.
     
  d) To evaluate annually the performance of the other executive officers of the Company in light of the goals and objectives of the Company’s compensation plans, and either as a Committee or together with the other independent directors (as directed by the Board) determine and approve the compensation of such other executive officers. To the extent that long-term incentive compensation is a component of such executive officer’s compensation, the Committee shall consider all relevant factors in determining the appropriate level of such compensation, including the factors applicable with respect to the Chief Executive Officer.

 

 C: 
 2 
   

 

  e) To evaluate annually the appropriate level of compensation for Board and Committee service by non-employee directors.
     
  f) To review and approve any severance or termination arrangements to be made with any executive officer of the Company.
     
  g) To perform such duties and responsibilities as may be assigned to the Board or the Committee under the terms of any executive compensation plan.
     
  h) To review perquisites or other personal benefits to the Company’s executive officers and directors and recommend any changes to the Board.
     
  i) To review compensation arrangements for the Company’s employees to evaluate whether incentive and other forms of pay encourage unnecessary or excessive risk taking, and review and discuss, at least annually, the relationship between risk management policies and practices, corporate strategy and the Company’s compensation arrangements.
     
  j) To review and approve the description of executive compensation included in the Company’s annual report on Form 10-KF.
     
  k) To perform such other functions as assigned by law, the Company’s articles of incorporation or bylaws or the Board.

 

B. General Compensation and Employee Benefit Plans

 

The Committee shall have the following duties and responsibilities with respect to the Company’s general compensation and employee benefit plans, including incentive compensation and equity-based plans:

 

  a) To review at least annually the goals and objectives of the Company’s general compensation plans and other employee benefit plans, including incentive-compensation and equity-based plans, and amend, or recommend that the Board amend, these goals and objectives if the Committee deems it appropriate.
     
  b) To review at least annually the Company’s general compensation plans and other employee benefit plans, including incentive-compensation and equity-based plans, in light of the goals and objectives of these plans, and recommend that the Board amend these plans if the Committee deems it appropriate.

 

 C: 
 3 
   

 

  c) To review all equity-compensation plans to be submitted for shareholder approval under the Nasdaq listing standards, and to review and, in the Committee’s sole discretion, approve all equity-compensation plans that are exempt from such shareholder approval requirement.
     
  d) To perform such duties and responsibilities as may be assigned to the Board or the Committee under the terms of any compensation or other employee benefit plan, including any incentive-compensation or equity-based plan.

 

V. ROLE OF CHIEF EXECUTIVE OFFICER

 

The Chief Executive Officer may make, and the Committee may consider, recommendations to the Committee regarding the Company’s compensation and employee benefit plans and practices, including its executive compensation plans, its incentive compensation and equity-based plans with respect to executive officers other than the Chief Executive Officer and the Company’s director compensation arrangements.

 

VI. EVALUATION OF THE COMMITTEE

 

The Committee shall, no less frequently than annually, evaluate its own performance. In conducting this review, the Committee shall evaluate whether this Charter appropriately addresses the matters that are or should be within its scope and shall recommend such changes as it deems necessary or appropriate to the Board for its consideration. The Committee shall address all matters that the Committee considers relevant to its performance, including at least the following: the adequacy, appropriateness and quality of the information and recommendations presented by the Committee to the Board, the manner in which they were discussed or debated, and whether the number and length of meetings of the Committee were adequate for the Committee to complete its work in a thorough and thoughtful manner.

 

The Committee shall deliver to the Board a report, which may be oral, setting forth the results of its evaluation, including any recommended amendments to this Charter and any recommended changes to the Company’s or the Board’s policies or procedures.

 

VII. INVESTIGATIONS AND STUDIES; OUTSIDE ADVISERS

 

The Committee may conduct or authorize investigations into or studies of matters within the Committee’s scope of responsibilities, and may, in its sole discretion, retain or obtain the advice of a compensation consultant, legal counsel or other adviser. The Committee shall be directly responsible for the appointment, compensation and oversight of the work of any compensation consultant, legal counsel or other adviser retained by the Committee, the expense of which shall be borne by the Company. The Committee may select a compensation consultant, legal counsel or other adviser to the Committee, other than in-house legal counsel, only after taking into consideration all factors relevant to that person’s independence from management, including the following:

 

  a) The provision of other services to the Company by the person that employs the compensation consultant, legal counsel or other adviser;

 

 C: 
 4 
   

 

  b) The amount of fees received from the Company by the person that employs the compensation consultant, legal counsel or other adviser, as a percentage of the total revenue of the person that employs the compensation consultant, legal counsel or other adviser;
     
  c) The policies and procedures of the person that employs the compensation consultant, legal counsel or other adviser that are designed to prevent conflicts of interest;
     
  d) Any business or personal relationship of the compensation consultant, legal counsel or other adviser with a member of the Committee;
     
  e) Any stock of the Company owned by the compensation consultant, legal counsel or other adviser; and
     
  f) Any business or personal relationship of the compensation consultant, legal counsel, other adviser or the person employing the adviser with an executive officer of the Company.

 

The Committee shall conduct the independence assessment with respect to any compensation consultant, legal counsel or other adviser that provides advice to the Committee, other than: (1) in-house legal counsel; and (2) any compensation consultant, legal counsel or other adviser whose role is limited to the following activities for which no disclosure would be required under Item 407(e)(3)(iii) of Regulation S-K: consulting on any broad-based plan that does not discriminate in scope, terms, or operation, in favor of executive officers or directors of the Company, and that is available generally to all salaried employees; or providing information that either is not customized for the Company or that is customized based on parameters that are not developed by the compensation consultant, and about which the compensation consultant does not provide advice.

 

Nothing herein requires a compensation consultant, legal counsel or other compensation adviser to be independent, only that the Committee consider the enumerated independence factors before selecting or receiving advice from a compensation consultant, legal counsel or other compensation adviser. The Committee may select or receive advice from any compensation consultant, legal counsel or other compensation adviser it prefers, including ones that are not independent, after considering the six independence factors outlined above.

 

Nothing herein shall be construed: (1) to require the Committee to implement or act consistently with the advice or recommendations of the compensation consultant, legal counsel or other adviser to the Committee; or (2) to affect the ability or obligation of the Committee to exercise its own judgment in fulfillment of its duties.

 

* * *

 

While the members of the Committee have the duties and responsibilities set forth in this Charter, nothing contained in this Charter is intended to create, or should be construed as creating, any responsibility or liability of members of the Committee, except to the extent otherwise provided under applicable federal or state law.

 

 C: 
 5 

 

 


22 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

11/22/23  Kraig Biocraft Laboratories, Inc. S-1/A                 67:13M                                    M2 Compliance LLC/FA
 9/01/23  Kraig Biocraft Laboratories, Inc. POS AM                67:13M                                    M2 Compliance LLC/FA
 9/01/23  Kraig Biocraft Laboratories, Inc. S-1/A                 67:13M                                    M2 Compliance LLC/FA
 6/06/23  Kraig Biocraft Laboratories, Inc. S-1/A                 66:13M                                    M2 Compliance LLC/FA
 5/09/23  Kraig Biocraft Laboratories, Inc. S-1/A                  1:2.2M                                   M2 Compliance LLC/FA
 4/27/23  Kraig Biocraft Laboratories, Inc. S-1/A                  1:2.2M                                   M2 Compliance LLC/FA
 4/14/23  Kraig Biocraft Laboratories, Inc. S-1/A                 65:9.9M                                   M2 Compliance LLC/FA
 4/14/23  Kraig Biocraft Laboratories, Inc. POS AM                65:9.1M                                   M2 Compliance LLC/FA
12/01/22  Kraig Biocraft Laboratories, Inc. S-1/A                 65:14M                                    M2 Compliance LLC/FA
 5/25/22  Kraig Biocraft Laboratories, Inc. S-1/A                 64:12M                                    M2 Compliance LLC/FA
 4/14/22  Kraig Biocraft Laboratories, Inc. S-1/A                 65:10M                                    M2 Compliance LLC/FA
 3/23/22  Kraig Biocraft Laboratories, Inc. S-1/A                 65:9.7M                                   M2 Compliance LLC/FA
 2/10/22  Kraig Biocraft Laboratories, Inc. S-1                   67:13M                                    M2 Compliance LLC/FA
12/03/21  Kraig Biocraft Laboratories, Inc. S-1/A                 64:13M                                    M2 Compliance LLC/FA
 8/25/21  Kraig Biocraft Laboratories, Inc. S-1/A                 63:12M                                    M2 Compliance LLC/FA
 5/26/21  Kraig Biocraft Laboratories, Inc. S-1/A                 86:9.3M                                   M2 Compliance LLC/FA
 4/15/21  Kraig Biocraft Laboratories, Inc. S-1/A                  1:74K                                    M2 Compliance LLC/FA
 4/14/21  Kraig Biocraft Laboratories, Inc. S-1/A                  2:161K                                   M2 Compliance LLC/FA
 4/05/21  Kraig Biocraft Laboratories, Inc. S-1                   63:6M                                     M2 Compliance LLC/FA
 2/18/21  Kraig Biocraft Laboratories, Inc. S-1/A                 78:9.1M                                   M2 Compliance LLC/FA
 2/08/21  Kraig Biocraft Laboratories, Inc. S-1/A                 78:9.1M                                   M2 Compliance LLC/FA
 8/24/20  Kraig Biocraft Laboratories, Inc. S-1/A                 68:7.8M                                   M2 Compliance LLC/FA
Top
Filing Submission 0001493152-20-010402   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Tue., Apr. 30, 4:51:22.2pm ET